CZ45498A3 - Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu - Google Patents

Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu Download PDF

Info

Publication number
CZ45498A3
CZ45498A3 CZ98454A CZ45498A CZ45498A3 CZ 45498 A3 CZ45498 A3 CZ 45498A3 CZ 98454 A CZ98454 A CZ 98454A CZ 45498 A CZ45498 A CZ 45498A CZ 45498 A3 CZ45498 A3 CZ 45498A3
Authority
CZ
Czechia
Prior art keywords
antibody
ser
antiselectin
selectin
wall
Prior art date
Application number
CZ98454A
Other languages
Czech (cs)
English (en)
Inventor
Anton Haselbeck
Günther Schumacher
Man Sung Co
Ulrich Martin
Original Assignee
Protein Design Labs, Inc.
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs, Inc., Boehringer Mannheim Gmbh filed Critical Protein Design Labs, Inc.
Publication of CZ45498A3 publication Critical patent/CZ45498A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ98454A 1995-08-17 1996-08-14 Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu CZ45498A3 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95112895 1995-08-17
EP95114696 1995-09-19
US57895395A 1995-12-27 1995-12-27

Publications (1)

Publication Number Publication Date
CZ45498A3 true CZ45498A3 (cs) 1999-01-13

Family

ID=27236574

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ98454A CZ45498A3 (cs) 1995-08-17 1996-08-14 Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu

Country Status (11)

Country Link
EP (1) EP0868197B1 (2)
JP (1) JP3604699B2 (2)
AT (1) ATE265861T1 (2)
AU (1) AU6773596A (2)
CA (1) CA2229140A1 (2)
CZ (1) CZ45498A3 (2)
DE (1) DE69632407T2 (2)
HU (1) HUP9901673A3 (2)
PL (1) PL187090B1 (2)
WO (1) WO1997006822A1 (2)
ZA (1) ZA966954B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2305192A (en) * 1991-06-25 1993-01-25 Dana-Farber Cancer Institute Monoclonal antibody to lymphocyte-associated cell surface protein
WO1993002698A1 (en) * 1991-07-29 1993-02-18 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to leukocyte adhesion molecule-1
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
AU2185195A (en) * 1993-11-30 1995-06-19 Protein Design Labs, Inc. Reperfusion therapy using antibodies to L-selectin

Also Published As

Publication number Publication date
PL325012A1 (en) 1998-07-06
JPH10510553A (ja) 1998-10-13
PL187090B1 (pl) 2004-05-31
EP0868197B1 (en) 2004-05-06
ATE265861T1 (de) 2004-05-15
HUP9901673A3 (en) 2001-06-28
CA2229140A1 (en) 1997-02-27
WO1997006822A1 (en) 1997-02-27
DE69632407D1 (de) 2004-06-09
ZA966954B (en) 1998-02-16
DE69632407T2 (de) 2005-06-02
EP0868197A1 (en) 1998-10-07
HUP9901673A2 (hu) 1999-08-30
JP3604699B2 (ja) 2004-12-22
EP0868197A4 (2) 1998-11-18
AU6773596A (en) 1997-03-12

Similar Documents

Publication Publication Date Title
FI120721B (fi) IL-6-antagonistin käyttö farmaseuttisen koostumuksen valmistamiseksi nivelreuman hoitamiseksi
Kroshus et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
DE69932600T2 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
US8513185B2 (en) Inhibition of TREM receptor signaling with peptide variants
US20240252631A1 (en) Methods of using activin receptor type ii signaling inhibitors
JP5737826B2 (ja) Ｖｅｇｆの阻害による貧血の処置
KR20090076960A (ko) 용혈성 빈혈 치료법
WO2001015731A1 (en) Compositions and methods for the treatment of sepsis using antibodies to c5a
CZ45498A3 (cs) Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu
ES2213141T3 (es) Anticuerpos con especificidad hacia multiples moleculas de adhesion.
JP4339405B2 (ja) 予防・治療剤
EP0573510B1 (en) Anti-growth factor antibodies in the treatment of vascular stenosis
WO2025122830A1 (en) Methods of using activin receptor type ii signaling inhibitors
AU746888B2 (en) Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
US20020098183A1 (en) Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation
TW520289B (en) Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation
US5843441A (en) Use of endothelial-leukocyte adhesion molecule-1 specific antibodies in the treatment of asthma
US20110142839A1 (en) Treatment of pulmonary edema
Kudlová et al. Expression of an Activated Form of Integrin beta~ 2 Chain CD18 in Cardiac Surgical Operations
CN119255817A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
JPWO2021211418A5 (2)
CN114989300A (zh) 抗tigit抗体在治疗肿瘤或癌症中的应用
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法
MX2008004901A (es) Agentes para suprimir el daño a islotes trasplantados despues del trasplante del islote.
MXPA96004715A (en) Use of agents that block the molecular interaction / receiver adhesion interaction in the treatment of viral infections respirator

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic